Histone deacetylases (HDACs) have proven to be a promising target for drug intervention, and there are a number of HDAC inhibitors (HDACi) currently being tested at various preclinical and clinical stages. HDACi were primarily developed as anti-tumor agents for cancer, but many are now being explored for treating neurologic, immunologic, metabolic, inflammatory and cardiovascular disorders. More recently, they are being developed as combination treatments along with small molecule cancer immunotherapy agents. However, much remains to be elucidated about the functional implications of modulating HDACs and understanding the signaling pathways that are triggered downstream. Cambridge Healthtech Institute’s conference on Next-Generation Histone Deacetylase Inhibitors tracks both the scientific and clinical progress being made to better understand the cellular function of this complex drug target family. The interactive sessions and panel discussions are all geared to provide ample opportunity for active networking, brainstorming and collaborating.
- Next-Generation Histone Deacetylase Inhibitors
- Insights into emerging HDAC biology
- HDACi for cancer immunotherapy and combination therapies
- Exploiting new chemistries and screening platforms
|Date||27 Sep 2017|
|Location||The Westin Copley Place|
Boston, Massachusetts, USA